The FDA has accepted Theravance Biopharma‘s (NSDQ:TBPH) marketing application for revefenacin, an inhaled long-acting muscarinic antagonist designed to treat chronic obstructive pulmonary disease.
The FDA is slated to make a decision about the once-daily treatment by Nov. 13.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA to review Theravance’s application for once-daily COPD med appeared first on MassDevice.